Medicalgorithmics Q3 2026 EBITDA rises to PLN 1.6 million; revenue jumps 52% year — on — year to PLN 10.9 million

Medicalgorithmics posted Q3 2026 consolidated sales revenue of PLN 10.9 million, up 52% year-on-year. EBITDA rose to PLN 1.6 million, up 9% versus Q2 2026. * US revenue climbed to PLN 4.4 million, up 102% year-on-year; the company analyzed more than 121,000 ECG studies. Extended a 12-month contract with its largest customer through July 15, 2028, with more favorable rates per completed session. Secured access to a loan of up to PLN 10 million and signed a three-year deal with a US remote cardiac monitoring platform provider. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicalgorithmics SA published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein. (C)